Table 1.
Patient characteristics according to pre-transplantation diabetes and obesity.
| Characteristic | Control group (N = 29,208) | Obesity (N = 5228) | Diabetes (N = 1415) | Obesity + Diabetes (N = 688) |
|---|---|---|---|---|
| Patient age in years, median (min-max) [IQR] | 54.3 (18–82.5) [41.4–62.7] | 53.8 (18–76.8) [43.2–61.5] | 61.5 (18–83.8) [55.1–66.4] | 59.5 (20.8–76.2) [53.8–64.2] |
| Patient sex, N (%) | ||||
| Male | 17,062 (58.5%) | 3027 (57.9%) | 1007 (71.2%) | 451 (65.7%) |
| Female | 12118 (41.5%) | 2198 (42.1%) | 407 (28.8%) | 235 (34.3%) |
| Missing | 28 | 3 | 1 | 2 |
| Karnofsky score, N (%) | ||||
| ≥90 | 20,208 (72.3%) | 3672 (73.4%) | 825 (61.6%) | 433 (65.8%) |
| <90 | 7752 (27.7%) | 1331 (26.6%) | 514 (38.4%) | 225 (34.2%) |
| Missing | 1248 | 225 | 76 | 30 |
| HCT-CI, N (%) | ||||
| 0 | 16,769 (59.4%) | 2243 (44.6%) | 0 (0%) | 0 (0%) |
| 1–2 | 5310 (18.8%) | 1700 (33.8%) | 630 (51%) | 298 (51.3%) |
| 3+ | 6134 (21.7%) | 1090 (21.7%) | 605 (49%) | 283 (48.7%) |
| Missing | 995 | 195 | 180 | 107 |
| Renal comorbidity (moderate/severe)a, N (%) | ||||
| Yes | 319 (1.1%) | 72 (1.4%) | 45 (3.4%) | 22 (3.5%) |
| No | 28736 (98.9%) | 5130 (98.6%) | 1271 (96.6%) | 608 (96.5%) |
| Missing | 153 | 26 | 99 | 58 |
| Cardiac comorbidityb, N (%) | ||||
| Yes | 1531 (5.3%) | 309 (5.9%) | 217 (16.3%) | 104 (16.3%) |
| No | 27,548 (94.7%) | 4896 (94.1%) | 1117 (83.7%) | 534 (83.7%) |
| Missing | 129 | 23 | 81 | 50 |
| Cerebrovascular diseasec, N (%) | ||||
| Yes | 458 (1.6%) | 97 (1.9%) | 56 (4.3%) | 16 (2.6%) |
| No | 28,639 (98.4%) | 5102 (98.1%) | 1255 (95.7%) | 608 (97.4%) |
| Missing | 111 | 29 | 104 | 64 |
| Body mass index in kg/m2, median (min-max) [IQR] | 24.2 (12.9–30) [21.9–26.5] | 32.5 (30–65.9) [31.1–34.9] | 25.6 (12.1–30) [23.5–27.7] | 32.9 (30–55.1) [31.2–35.6] |
| Diagnosis, N (%) | ||||
| Acute leukemia | 17,183 (58.8%) | 2989 (57.2%) | 787 (55.6%) | 374 (54.4%) |
| Chronic leukemia | 1176 (4%) | 266 (5.1%) | 55 (3.9%) | 29 (4.2%) |
| Lymphoma | 3668 (12.6%) | 629 (12%) | 128 (9%) | 65 (9.4%) |
| Plasma cell disorders | 792 (2.7%) | 182 (3.5%) | 37 (2.6%) | 22 (3.2%) |
| MDS/MPN | 6389 (21.9%) | 1162 (22.2%) | 408 (28.8%) | 198 (28.8%) |
| Disease risk index, N (%) | ||||
| Low | 2519 (9.2%) | 560 (11.4%) | 94 (7.1%) | 48 (7.5%) |
| Intermediate | 17,315 (63.1%) | 3139 (63.7%) | 832 (63.1%) | 416 (65.1%) |
| High | 6428 (23.4%) | 1060 (21.5%) | 332 (25.2%) | 155 (24.3%) |
| Very High | 1165 (4.2%) | 170 (3.4%) | 60 (4.6%) | 20 (3.1%) |
| Missing | 1781 | 299 | 97 | 49 |
| Donor type, N (%) | ||||
| Identical sibling | 9034 (30.9%) | 1652 (31.6%) | 406 (28.7%) | 211 (30.7%) |
| MUD 10/10 | 11,797 (40.4%) | 2140 (40.9%) | 586 (41.4%) | 309 (44.9%) |
| MMUD 9/10 | 2968 (10.2%) | 541 (10.3%) | 137 (9.7%) | 75 (10.9%) |
| MMUD 8/10 or less | 383 (1.3%) | 80 (1.5%) | 16 (1.1%) | 12 (1.7%) |
| Haploidentical | 5026 (17.2%) | 815 (15.6%) | 270 (19.1%) | 81 (11.8%) |
| Cell source, N (%) | ||||
| Bone marrow | 3071 (10.5%) | 385 (7.4%) | 110 (7.8%) | 21 (3.1%) |
| Peripheral blood | 26,137 (89.5%) | 4843 (92.6%) | 1305 (92.2%) | 667 (96.9%) |
| Conditioning intensity, N (%) | ||||
| Myeloablative | 14,716 (50.8%) | 2530 (48.9%) | 540 (38.6%) | 247 (36.6%) |
| Reduced intensity | 14,237 (49.2%) | 2646 (51.1%) | 858 (61.4%) | 427 (63.4%) |
| Missing | 255 | 52 | 17 | 14 |
| Total-body irradiation, N (%) | 6425 (22%) | 1090 (20.8%) | 254 (18%) | 126 (18.3%) |
| In vivo T-cell depletion | ||||
| ATG/Campath | 16,151 (55.7%) | 3061 (58.9%) | 816 (58%) | 424 (61.9%) |
| No | 12,858 (44.3%) | 2140 (41.1%) | 591 (42%) | 261 (38.1%) |
| Missing | 199 | 27 | 8 | 3 |
ATG anti-thymocyte globulin, HCT-CI hematopoietic cell transplantation-specific comorbidity index, IQR inter-quartile range, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasm, (M)MUD (mis)matched unrelated donor.
aDefined from the HCT-CI as having serum creatinine >2 mg/dL (>177 μmol/L), on dialysis, or prior renal transplantation.
bDefined from the HCT-CI as having coronary artery disease, congestive heart failure, myocardial infarction, or ejection fraction ≤ 50%.
cDefined from the HCT-CI as having had a transient ischemic attack or cerebrovascular accident.